Abstract 3709: Second cancers following Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma in the United States: analysis of Surveillance, Epidemiology and End Results (SEER) registry data, 1992 - 2011

Waldenström macroglobulinemia (WM) is a subtype of lymphoplasmacytic lymphoma (LPL) that features secretion of monoclonal immunoglobulin type M (IgM) in the blood. WM/LPL occurs most commonly in elderly (median, 73 years) white males and is characterized by an indolent course and relatively long survival. Thus, WM/LPL patients may be at risk for development of subsequent cancers. We used data from the National Cancer Institute Surveillance, Epidemiology and End Results (SEER) program to evaluate the risk of subsequent primary cancer in more than 3800 patients diagnosed with WM or LPL during the 20-year period, 1992 - 2011. We calculated observed-to-expected (O/E) standardized incidence ratios, together with 95% confidence intervals (95%CI), for invasive cancers occurring in these individuals. We found that the overall risk for second cancers was significantly increased among survivors of WM/LPL (O/E = 1.49; 95%CI 1.37-1.62) and risk increased with time since diagnosis. Increased risk was observed for both solid tumors (O/E = 1.21; 95%CI 1.09-1.33) and hematolymphoid cancers (O/E = 4.20; 95%CI 3.54-4.95). Significantly increased site-specific risks were seen for cancers of the lung and bronchus, melanoma, non-epithelial skin, and thyroid as well as for Hodgkin and non-Hodgkin lymphoma, multiple myeloma, and acute myeloid leukemia. Sample size limited subset analysis; however, overall increased risk was observed in all race (white, black, Asian/Pacific Islanders) and gender ca...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Epidemiology Source Type: research